Prolific Machines
Prolific Machines is pioneering the use of optogenetics and AI-driven bioprocess optimization to revolutionize biomanufacturing. Their mission is to illuminate biology’s limitless potential for a healthier tomorrow by enabling the production of next-generation therapeutics and broadening patient access to life-altering medicines. Founded in 2020, the company has developed a unique Photomolecular™ platform that uses light to precisely control cellular functions, boosting yields, improving quality, and enabling the manufacture of complex biotherapeutics. With a focus on strategic partnerships, Prolific Machines collaborates with innovators in biopharma and advanced nutrition, offering flexible, scalable solutions and in-house cell line development up to 200-liter pilot scale. The company is recognized for its commitment to safety, innovation, and a collaborative, diverse team culture.
Industries
Nr. of Employees
small (1-50)
Products
Add-on illumination systems for bioreactors
Modular illumination hardware to deliver configurable light wavelengths, intensities, and patterns to cell cultures across benchtop, single-use, and pilot stainless-steel reactors.
Optogenetic toolkit and engineered cell lines
A suite of engineered light-inducible promoters, receptor-control constructs, and cell lines enabling tunable expression, metabolic optimization, and receptor regulation for bioproduction.
AI-driven controller software
Software that models pathway dynamics and acts as a controller to continuously sense activation and adjust illumination via model-predictive algorithms.
Add-on illumination systems for bioreactors
Modular illumination hardware to deliver configurable light wavelengths, intensities, and patterns to cell cultures across benchtop, single-use, and pilot stainless-steel reactors.
Optogenetic toolkit and engineered cell lines
A suite of engineered light-inducible promoters, receptor-control constructs, and cell lines enabling tunable expression, metabolic optimization, and receptor regulation for bioproduction.
AI-driven controller software
Software that models pathway dynamics and acts as a controller to continuously sense activation and adjust illumination via model-predictive algorithms.
Services
Engineering cell lines with light-inducible constructs to control transcription, secretion, receptor signaling, metabolic pathways, and PTMs for target protein production.
Design and deployment of add-on illumination hardware for benchtop reactors, 50 L single-use systems, and up to 200 L stainless-steel reactors to deliver precise light inputs.
Real-time monitoring and model-predictive control software that dynamically adjusts illumination based on process data to maximize yield and maintain product quality.
Fee-for-service R&D projects with defined milestones to validate optogenetic strategies for difficult-to-express proteins and other biotherapeutic targets.
Engineering cell lines with light-inducible constructs to control transcription, secretion, receptor signaling, metabolic pathways, and PTMs for target protein production.
Design and deployment of add-on illumination hardware for benchtop reactors, 50 L single-use systems, and up to 200 L stainless-steel reactors to deliver precise light inputs.
Real-time monitoring and model-predictive control software that dynamically adjusts illumination based on process data to maximize yield and maintain product quality.
Fee-for-service R&D projects with defined milestones to validate optogenetic strategies for difficult-to-express proteins and other biotherapeutic targets.
Expertise Areas
- Optogenetic cell line engineering
- Light-driven bioprocessing
- Bioreactor illumination system design
- AI-driven closed-loop process control
Key Technologies
- Optogenetics (light-sensitive protein systems)
- Light-controlled gene expression
- Model predictive control
- Closed-loop sensing and control software
News & Updates
Prolific Machines was selected to join the FDA's Emerging Technology Program, advancing its novel biomanufacturing platform.
Appointment of a former Catalent CSO to the Board of Directors, strengthening leadership for future growth.
Completion of optogenetic bioproduction at 200L scale, marking the world’s largest demonstration of optogenetics to date.
Christina Perry joins as CFO, setting the stage for commercial ramp-up in biopharmaceuticals.
TIME recognizes Prolific Machines’ photomolecular platform as one of the Best Inventions of 2024.
Article in Grow Everything about Prolific’s approach to using light for cellular control.
Prolific Machines was selected to join the FDA's Emerging Technology Program, advancing its novel biomanufacturing platform.
Appointment of a former Catalent CSO to the Board of Directors, strengthening leadership for future growth.
Completion of optogenetic bioproduction at 200L scale, marking the world’s largest demonstration of optogenetics to date.
Christina Perry joins as CFO, setting the stage for commercial ramp-up in biopharmaceuticals.
TIME recognizes Prolific Machines’ photomolecular platform as one of the Best Inventions of 2024.
Article in Grow Everything about Prolific’s approach to using light for cellular control.